Rhizen Pharmaceuticals S.A.

Alembic Pharmaceuticals -backed Rhizen Pharmaceuticals faces a significant setback after partner TG Therapeutics pulled its approved phosphatidylinositol 3-kinase (PI3K) inhibitor Ukoniq (umbralis

Alembic Pharmaceuticals Limited -backed Rhizen Pharmaceuticals faces a significant setback after partner TG Therapeutics, Inc. pulled its approved phosphatidylinositol 3-kinase (PI3K) inhibitor Uk

The biopharma industry outdid itself in 2021, launching a record 97 novel active substances in their first markets, and smashing the previous year’s record new product tally of 83. COVID-19 products/v

If the accelerated US Food and Drug Administration approval for Ukoniq (umbralisib) for two lymphoma types marked a “transformational” moment for TG Therapeutics, Inc. , shaping it from being purely